{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:41:17Z","timestamp":1793032877710,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ijpx.2026.100677","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:42:54Z","timestamp":1790836974000},"page":"100677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Applicability of a miniaturized precipitation assay as an early-stage screening tool for prototype formulation development"],"prefix":"10.1016","volume":"12","author":[{"given":"Sara","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Krollik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Spanheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Weitschies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2026.100677_bb0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejpb.2018.07.003","article-title":"Introduction to the OrBiTo decision tree to select the most appropriate in vitro methodology for release testing of solid oral dosage forms during development","volume":"130","author":"Andreas","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejps.2013.08.027","article-title":"A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption","volume":"57","author":"Augustijns","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0015","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1002\/jps.24177","article-title":"Application and validation of an advanced gastrointestinal in vitro model for the evaluation of drug product performance in pharmaceutical development","volume":"103","author":"Barker","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/annotation\/10ae05dc-90cb-46f1-aa2b-e63eb4a132e2","article-title":"Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations","volume":"8","author":"Beig","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpx.2026.100677_bb0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. B. Methodol."},{"key":"10.1016\/j.ijpx.2026.100677_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijpharm.2017.12.025","article-title":"The artificial membrane insert system as predictive tool for formulation performance evaluation","volume":"537","author":"Berben","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpharm.2012.11.026","article-title":"Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues","volume":"453","author":"Bevernage","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ijpx.2026.100677_bb0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1208\/s12248-022-00687-0","article-title":"State of the art and uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): new additions, revisions, and citation references","volume":"24","author":"Bocci","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpx.2026.100677_bb0045","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1021\/acs.molpharmaceut.9b00406","article-title":"Prediction of bioequivalence and food effect using flux- and solubility-based methods","volume":"16","author":"Borb\u00e1s","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.104967","article-title":"Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems","volume":"137","author":"Boyd","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0055","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2017.04.029","article-title":"Gastrointestinal behavior of itraconazole in humans - part 1: supersaturation from a solid dispersion and a cyclodextrin-based solution","volume":"525","author":"Brouwers","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0065","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.xphs.2022.12.010","article-title":"When interactions between bile salts and cyclodextrin cause a negative food effect: dynamic dissolution\/permeation studies with Itraconazole (Sporanox\u00ae) and biomimetic media","volume":"112","author":"Cuoco","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0070","author":"FDA, Center for Drug Evaluation and Research"},{"key":"10.1016\/j.ijpx.2026.100677_bb0075","author":"FDA, Center for Drug Evaluation and Research"},{"key":"10.1016\/j.ijpx.2026.100677_bb0080","author":"FDA, Center for Drug Evaluation and Research"},{"key":"10.1016\/j.ijpx.2026.100677_bb0085","author":"FDA, Center for Drug Evaluation and Research"},{"key":"10.1016\/j.ijpx.2026.100677_bb0090","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jphp.12875","article-title":"Development, current applications and future roles of biorelevant two-stage in vitro testing in drug development","volume":"70","author":"Fiolka","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100677_bb0095","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1016\/j.xphs.2020.04.023","article-title":"Biorelevant two-stage in vitro testing for rDCS classification and in PBPK modeling-case example ritonavir","volume":"109","author":"Fiolka","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0100","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100677_bb0105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1214\/09-STS301","article-title":"The impact of Levene\u2019s test of equality of variances on statistical theory and practice","volume":"24","author":"Gastwirth","year":"2009","journal-title":"Stat. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1185\/0300799009117017","article-title":"A new formulation of fenofibrate: suprabioavailable tablets","volume":"16","author":"Guichard","year":"2000","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ijpx.2026.100677_bb0115","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1021\/acs.molpharmaceut.7b00740","article-title":"Absorptive dissolution testing of supersaturating systems: impact of absorptive sink conditions on solution phase behavior and mass transport","volume":"14","author":"Hate","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejps.2015.05.023","article-title":"Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential","volume":"77","author":"Hens","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0125","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/jps.24690","article-title":"Supersaturation and precipitation of posaconazole upon entry in the upper small intestine in humans","volume":"105","author":"Hens","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejps.2018.01.039","article-title":"Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): an in vitro-in silico-in vivo approach","volume":"115","author":"Hens","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejpb.2016.01.007","article-title":"Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats","volume":"101","author":"Holm","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11095-018-2441-2","article-title":"Crystallization from supersaturated solutions: role of lecithin and composite simulated intestinal fluid","volume":"35","author":"Indulkar","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100677_bb0145","author":"Janssen Pharmaceutica N.V. 2340 Beerse"},{"key":"10.1016\/j.ijpx.2026.100677_bb0150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2018.12.013","article-title":"Automated small-scale in vitro transfer model as screening tool for the prediction of in vivo-dissolution and precipitation of poorly solubles","volume":"556","author":"Jede","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0155","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1021\/acs.molpharmaceut.9b00534","article-title":"Improved prediction of in vivo supersaturation and precipitation of poorly soluble weakly basic drugs using a biorelevant bicarbonate buffer in a gastrointestinal transfer model","volume":"16","author":"Jede","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2010.10.012","article-title":"Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles","volume":"77","author":"Juenemann","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1208\/s12248-010-9203-3","article-title":"The use of biorelevant dissolution media to forecast the in vivo performance of a drug","volume":"12","author":"Klein","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpx.2026.100677_bb0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1211\/0022357022511","article-title":"Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine","volume":"56","author":"Kostewicz","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100677_bb0175","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1021\/acs.molpharmaceut.7b01143","article-title":"In vitro, in silico, and in vivo assessments of intestinal precipitation and its impact on bioavailability of a BCS class 2 basic compound","volume":"15","author":"Kou","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2015.11.012","article-title":"An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation","volume":"82","author":"Kourentas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0185","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijpharm.2016.10.018","article-title":"In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT","volume":"515","author":"Kourentas","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106165","article-title":"Application of tiny-TIM as a mechanistic tool to investigate the in vitro performance of different itraconazole formulations under physiologically relevant conditions","volume":"173","author":"L\u00f3pez M\u00e1rmol","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0195","article-title":"Precipitation as key parameter for early oral drug absorption predictions, Part II: development of a predictive model","volume":"213","author":"Mayer","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0200","article-title":"Precipitation as key parameter for early oral drug absorption predictions, part I: acquisition of critical data","volume":"213","author":"Mayer","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0205","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/mp200181v","article-title":"The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation","volume":"8","author":"Miller","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0210","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0215","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jphp.12951","article-title":"In vitro methods to assess drug precipitation in the fasted small intestine - a PEARRL review","volume":"71","author":"O'Dwyer","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100677_bb0220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2017.03.019","article-title":"In vitro biphasic dissolution tests and their suitability for establishing in vitro-in vivo correlations: a historical review","volume":"102","author":"Pestieau","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0225","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7150\/jca.17301","article-title":"Super aqueous solubility of albendazole in \u03b2-cyclodextrin for parenteral application in cancer therapy","volume":"8","author":"Pillai","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.ijpx.2026.100677_bb0230","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/jphp.12927","article-title":"Approaches to increase mechanistic understanding and aid in the selection of precipitation inhibitors for supersaturating formulations \u2013 a PEARRL review","volume":"71","author":"Price","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpx.2026.100677_bb0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1208\/s12248-020-00508-2","article-title":"Use of Physiologically Based Pharmacokinetic (PBPK) modeling for predicting drug-food interactions: an industry perspective","volume":"22","author":"Riedmaier","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpx.2026.100677_bb0240","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1128\/AAC.48.3.1051-1054.2004","article-title":"Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers","volume":"48","author":"Rigter","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2026.100677_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107047","article-title":"A physiologically based biopharmaceutics modeling (PBBM) framework for characterizing formulation-dependent food effects: Paving the road towards fed state virtual BE studies for itraconazole amorphous solid dispersions","volume":"209","author":"Rudolph","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0250","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/beheco\/ark016","article-title":"The unequal variance t-test is an underused alternative to Student's t-test and the Mann\u2013Whitney U test","volume":"17","author":"Ruxton","year":"2006","journal-title":"Behav. Ecol."},{"key":"10.1016\/j.ijpx.2026.100677_bb0255","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s11095-021-03153-2","article-title":"Dissolution kinetics of nifedipine-ionizable polymer amorphous solid dispersion: comparison between bicarbonate and phosphate buffers","volume":"38","author":"Sakamoto","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100677_bb0260","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.114.060061","article-title":"Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men","volume":"43","author":"Scheers","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpx.2026.100677_bb0265","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijpharm.2016.07.063","article-title":"Displacement of itraconazole from cyclodextrin complexes in biorelevant media: in vitro evaluation of supersaturation and precipitation behavior","volume":"511","author":"Stappaerts","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0270","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1021\/mp3003607","article-title":"Solid nanocrystalline dispersions of ziprasidone with enhanced bioavailability in the fasted state","volume":"9","author":"Thombre","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0275","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2012.02.004","article-title":"In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations","volume":"428","author":"Thombre","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2015.06.032","article-title":"Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone","volume":"213","author":"Thombre","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2026.100677_bb0285","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. (n.d.). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0290","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejpb.2007.05.010","article-title":"Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations","volume":"68","author":"Vogt","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2026.100677_bb0295","first-page":"28","article-title":"The generalization of \u2018student\u2019s\u2019 problem when several different population variances are involved","volume":"34","author":"Welch","year":"1947","journal-title":"Biometrika"},{"key":"10.1016\/j.ijpx.2026.100677_bb0300","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/jps.20198","article-title":"\u03b2-cyclodextrin reduces bioavailability of orally administered [3H]Benzo[a]pyrene in the rat","volume":"94","author":"Westerberg","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100677_bb0305","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1021\/acs.molpharmaceut.7b00552","article-title":"In vitro characterization of ritonavir drug products and correlation to human in vivo performance","volume":"14","author":"Xu","year":"2017","journal-title":"Mol. Pharm."}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726001970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726001970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:13:47Z","timestamp":1793031227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156726001970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":61,"alternative-id":["S2590156726001970"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100677","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applicability of a miniaturized precipitation assay as an early-stage screening tool for prototype formulation development","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100677"}}